<SEC-DOCUMENT>0001157523-13-000193.txt : 20130122
<SEC-HEADER>0001157523-13-000193.hdr.sgml : 20130121
<ACCEPTANCE-DATETIME>20130122093330
ACCESSION NUMBER:		0001157523-13-000193
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20130117
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130122
DATE AS OF CHANGE:		20130122

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANIKA THERAPEUTICS INC
		CENTRAL INDEX KEY:			0000898437
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				043145961
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14027
		FILM NUMBER:		13539154

	BUSINESS ADDRESS:	
		STREET 1:		236 WEST CUMMINGS PARK
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801
		BUSINESS PHONE:		6179326616

	MAIL ADDRESS:	
		STREET 1:		236 WEST CUMMINGS PARK
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANIKA RESEARCH INC
		DATE OF NAME CHANGE:	19930309
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a50538545.htm
<DESCRIPTION>ANIKA THERAPEUTICS, INC. 8-K
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2013 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-family: Times New Roman; font-size: 10pt">
    <hr style="width: 100%; color: #000000; height: 2.0 pt; text-align: center">


    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 17pt"><b>UNITED
      STATES</b></font><b><font style="font-family: Times New Roman; font-size: 17pt"><br style="font-family: Times New Roman; font-size: 17pt"></font><font style="font-family: Times New Roman; font-size: 17pt">SECURITIES
      AND EXCHANGE COMMISSION</font></b><font style="font-size: 10pt"><br style="font-size: 10pt"></font><font style="font-size: 12pt"><b>WASHINGTON,
      D.C. 20549</b></font><br><br><br><font style="font-family: Times New Roman; font-size: 17pt"><b>FORM
      8-K</b></font><br><br><br><font style="font-family: Times New Roman; font-size: 10pt">CURRENT
      REPORT</font><font style="font-family: Times New Roman; font-size: 10pt"><br style="font-family: Times New Roman; font-size: 10pt"></font><font style="font-family: Times New Roman; font-size: 10pt">Pursuant
      to Section 13 or 15(d) of the Securities Exchange Act of 1934</font><br><font style="font-family: Times New Roman; font-size: 10pt"><br style="font-family: Times New Roman; font-size: 10pt"></font><font style="font-family: Times New Roman; font-size: 10pt">Date
      of Report (Date of earliest event reported): January 17, 2013</font><font style="font-family: Times New Roman; font-size: 10pt"><br style="font-family: Times New Roman; font-size: 10pt"></font><br><br>
    </p>
    <div style="text-align:center">
    <table cellspacing="0" style="font-family: Times New Roman; font-size: 10pt; margin-left:auto;margin-right:auto; margin-bottom: 10.0px; width: 100%">
      <tr>
        <td valign="top" style="padding-left: 0.0px; text-align: center">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <font style="font-family: Times New Roman; font-size: 20pt"><b>Anika
            Therapeutics, Inc.</b></font>
          </p>
        </td>
      </tr>
      <tr>
        <td valign="top" style="padding-left: 0.0px; text-align: center">
          <p style="margin-top: 0px; margin-bottom: 0px">
            (Exact name of registrant as specified in its charter)
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <div style="text-align:center">
    <table cellspacing="0" style="font-family: Times New Roman; font-size: 10pt; margin-left:auto;margin-right:auto; width: 100%; margin-bottom: 10.0px">
      <tr>
        <td valign="bottom" style="padding-left: 0.0px; text-align: center; width: 33%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>Massachusetts</b>
          </p>
        </td>
        <td valign="bottom" style="padding-left: 0.0px; padding-right: 0.0px; text-align: center; white-space: nowrap; width: 34%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>000-21326</b>
          </p>
        </td>
        <td valign="bottom" style="padding-left: 0.0px; padding-right: 0.0px; text-align: center; white-space: nowrap; width: 33%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>04-314-5961</b>
          </p>
        </td>
      </tr>
      <tr>
        <td valign="top" style="padding-left: 0.0px; text-align: center; width: 33%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            (State or other jurisdiction<br>of incorporation)
          </p>
        </td>
        <td valign="top" style="padding-left: 0.0px; text-align: center; width: 34%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            (Commission File<br>Number)
          </p>
        </td>
        <td valign="top" style="padding-left: 0.0px; text-align: center; width: 33%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            (IRS Employer<br>Identification No.)
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <div style="text-align:center">
    <table cellspacing="0" style="font-family: Times New Roman; font-size: 10pt; margin-left:auto;margin-right:auto; width: 100%; margin-bottom: 10.0px">
      <tr>
        <td valign="top" style="padding-left: 0.0px; text-align: center; width: 40%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>32 Wiggins Avenue<br>Bedford, Massachusetts</b>
          </p>
        </td>
        <td valign="bottom" style="padding-left: 0.0px; text-align: center; width: 20%">
          &#160;
        </td>
        <td valign="bottom" style="padding-left: 0.0px; padding-right: 0.0px; text-align: center; white-space: nowrap; width: 40%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>01730</b>
          </p>
        </td>
      </tr>
      <tr>
        <td valign="top" style="padding-left: 0.0px; text-align: center; width: 40%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            (Address of principal executive offices)
          </p>
        </td>
        <td style="width: 20%">

        </td>
        <td valign="top" style="padding-left: 0.0px; text-align: center; width: 40%">
          (Zip Code)
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <p style="text-align: center; white-space: nowrap">
      Registrant&#8217;s telephone number, including area code:<b>&#160;&#160;(781)
      457-9000</b><br>
    </p>
    <p style="text-align: center">
      <br>
      <b>N/A</b><br>&#160;(Former name or former address, if changed since last
      report.)<br>
    </p>
    <p style="text-align: center">

    </p>
    <p>
      <font style="font-family: Times New Roman; font-size: 10pt">Check the
      appropriate box below if the Form 8-K filing is intended to
      simultaneously satisfy the filing obligations of the registrant under
      any of the following provisions:</font>
    </p>
    <p>
      <font style="font-family: Arial Unicode MS; font-size: 10pt">&#8414;</font>
      <font style="font-family: Times New Roman; font-size: 10pt">Written
      communications pursuant to Rule 425 under the Securities Act (17 CFR
      230.425)</font>
    </p>
    <p>
      <font style="font-family: Arial Unicode MS; font-size: 10pt">&#8414;</font>
      <font style="font-family: Times New Roman; font-size: 10pt">Soliciting
      material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)</font>
    </p>
    <p>
      <font style="font-family: Arial Unicode MS; font-size: 10pt">&#8414;</font>
      <font style="font-family: Times New Roman; font-size: 10pt">Pre-commencement
      communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
      240.14d-2(b))</font>
    </p>
    <p>
      <font style="font-family: Arial Unicode MS; font-size: 10pt">&#8414;</font>
      <font style="font-family: Times New Roman; font-size: 10pt">Pre-commencement
      communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
      240.13e-4(c))</font>
    </p>
    <div style="margin-right: 0pt; text-indent: 0pt; margin-left: 0pt; width: 100%; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      <b>Item 2.02 Results of Operations and Financial Condition.</b>
    </p>
    <p>
      On January 22, 2013, Anika Therapeutics, Inc. issued a press release
      reporting its preliminary unaudited total revenue for the quarter and
      year ended December 31, 2012.&#160;&#160;The press release has been furnished as
      Exhibit 99.1 to this Report on Form 8-K.
    </p>
    <p>
      <b>Item&#160;5.02.&#160;&#160;Departure of Directors or Certain Officers; Election of
      Directors; Appointment of Certain Officers; Compensatory Arrangements of
      Certain Officers.</b>
    </p>
    <p>
      On January 17, 2013, the Board of Directors of Anika Therapeutics, Inc.
      (the &#8220;Company&#8221;, or &#8220;Anika&#8221;) appointed Sylvia Cheung as the Chief
      Financial Officer, Treasurer, Secretary, principal financial officer and
      principal accounting officer of the Company, effective April 1,
      2013.&#160;&#160;Ms. Cheung will succeed Kevin W. Quinlan, current Chief Financial
      Officer, Treasurer, Secretary, principal financial officer and principal
      accounting officer of the company.&#160;&#160;Mr. Quinlan is leaving Anika
      effective March 31, 2013, after seven years of dedicated service, to
      pursue other professional opportunities.
    </p>
    <p>
      Ms. Cheung has over 16 years of financial and general management
      experience. Prior to her current position as Vice President of Strategic
      Processes, Cheung served as General Manager for the company&#8217;s
      Italy-based subsidiary, Anika Srl. She joined Anika as Controller in
      2005. In addition to fulfilling financial responsibilities as
      Controller, Cheung led the company&#8217;s integration of Anika Srl subsequent
      to its acquisition in 2009. Prior to Anika, she held a series of
      progressively responsible financial management positions at
      Transkaryotic Therapies, Inc. Cheung holds a bachelor&#8217;s of business
      administration in accounting from the University of Massachusetts in
      Amherst, a master&#8217;s in business administration from Boston University,
      and is a Certified Public Accountant (inactive).
    </p>
    <p>
      There are no other arrangements or understandings between Ms. Cheung and
      any other persons pursuant to which she was selected as the Company&#8217;s
      Chief Financial Officer, Treasurer, Secretary, principal financial
      officer and principal accounting officer.&#160;&#160;Additionally, there are no
      transactions involving the Company and Ms. Cheung that the Company would
      be required to report pursuant to Item 404(a) of Regulation S-K.
    </p>
    <p>
      On January 22, 2013, the Company issued a press announcing Ms. Cheung&#8217;s
      appointment as Chief Financial Officer of the Company.&#160;&#160;The full text of
      the press release is attached as Exhibit 99.1 to this Current Report on
      Form 8-K and is incorporated herein by reference.
    </p>
    <p>
      <b>Item&#160;9.01. Financial Statements and Exhibits.</b>
    </p>
    <p>
      (d) Exhibits
    </p>
    <p style="font-size: 10pt; margin-left: 30.0px">
      99.1 Press Release by Anika Therapeutics, Inc., dated January 22, 2013.
    </p>
    <div style="margin-right: 0pt; text-indent: 0pt; margin-left: 0pt; width: 100%; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>

    </p>
    <p style="text-align: left">
      <u><font style="font-family: Times New Roman; font-size: 10pt">SIGNATURES</font></u>
    </p>
    <p style="font-size: 10pt; text-indent: 30.0px">
      Pursuant to the requirements of the Securities Exchange Act of 1934, the
      registrant has duly caused this report to be signed on its behalf by the
      undersigned hereunto duly authorized.
    </p>
    <p>

    </p>
    <div style="text-align:center">
    <table cellspacing="0" style="font-family: Times New Roman; font-size: 10pt; margin-left:auto;margin-right:auto; width: 100%; margin-bottom: 10.0px">
      <tr>
        <td style="width: 50%">

        </td>
        <td valign="top" colspan="3" style="padding-left: 0.0px; text-align: left">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Anika Therapeutics, Inc.
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 50%">

        </td>
        <td valign="top" colspan="2" style="padding-left: 0.0px; text-align: left">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td style="width: 12%">

        </td>
      </tr>
      <tr>
        <td valign="top" style="padding-left: 0.0px; text-align: left; padding-bottom: 2.0px; width: 50%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Date: January 22, 2013
          </p>
        </td>
        <td valign="top" style="padding-left: 0.0px; text-align: left; padding-bottom: 2.0px; width: 8%">
          By:
        </td>
        <td valign="top" style="padding-left: 0.0px; text-align: left; width: 30%; border-bottom: solid black 1.0pt">
          <p style="margin-top: 0px; margin-bottom: 0px">
            /s/ Charles H. Sherwood
          </p>
        </td>
        <td style="width: 12%">

        </td>
      </tr>
      <tr>
        <td style="width: 50%">

        </td>
        <td valign="top" style="padding-left: 0.0px; text-align: left; width: 8%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Name:
          </p>
        </td>
        <td valign="top" colspan="2" style="padding-left: 0.0px; text-align: left">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Charles H. Sherwood
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 50%">

        </td>
        <td valign="top" style="padding-left: 0.0px; text-align: left; width: 8%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Title:
          </p>
        </td>
        <td valign="top" colspan="2" style="padding-left: 0.0px; text-align: left">
          <p style="margin-top: 0px; margin-bottom: 0px">
            President &amp; Chief Executive Officer
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
  </body>
</html>
<!--<!DOCTYPE html
     PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN"
     "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">-->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a50538545ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2013 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-family: Times New Roman; font-size: 8pt">
    <p style="text-align: right">
      <b>Exhibit 99.1</b>
    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 12pt"><b>Anika
      Therapeutics Names Sylvia Cheung as Chief Financial Officer</b></font>
    </p>
    <p style="text-align: center">
      <i><font style="font-family: Times New Roman; font-size: 12pt"><b>Provides
      Summary of Fourth Quarter and 2012 Preliminary Financial Results</b></font></i>
    </p>
    <p>
      BEDFORD, Mass.--(BUSINESS WIRE)--January 22, 2013--Anika Therapeutics,
      Inc. (Nasdaq: ANIK) today announced the appointment of Sylvia Cheung as
      the company&#8217;s Chief Financial Officer, effective April 1, 2013. Cheung,
      who has served as Anika&#8217;s Vice President for Strategic Processes since
      February 2012, will succeed Kevin W. Quinlan, who is leaving Anika
      effective March 31, 2013 to pursue other professional opportunities. The
      company also today provided its preliminary unaudited revenue results
      for the fourth quarter and full year ended December 31, 2012.
    </p>
    <p>
      Cheung, 38, brings to Anika more than 16 years of financial and general
      management experience. Prior to her current position as Vice President
      of Strategic Processes, Cheung served as General Manager for the
      company&#8217;s Italy-based subsidiary, Anika Srl. She joined Anika as
      Controller in 2005. In addition to fulfilling wide-ranging financial
      responsibilities as Controller, Cheung led the company&#8217;s integration of
      Anika Srl subsequent to its acquisition in 2009. Prior to Anika, she
      held a series of progressively responsible financial management
      positions at Transkaryotic Therapies, Inc. Cheung holds a bachelor of
      business administration degree in accounting from the University of
      Massachusetts in Amherst, a master&#8217;s degree in business administration
      from Boston University, and is a Certified Public Accountant (inactive).
    </p>
    <p>
      &#8220;Serving as our new Chief Financial Officer will enable Sylvia to apply
      her financial acumen and business experience not only in leading Anika&#8217;s
      finance team, but in playing a key role in our efforts to strategically
      position the company for growth,&#8221; said Charles H. Sherwood, Ph.D.,
      Anika&#8217;s President and Chief Executive Officer. &#8220;Sylvia has the ideal
      combination of talents, skills and experience &#8211; as well as a record of
      success as a member of Anika&#8217;s senior management team &#8211; to ensure
      continuity in the CFO position and help advance our company into the
      future.&#8221;
    </p>
    <p>
      &#8220;On behalf of the board of directors, I extend our thanks to Kevin
      Quinlan for his years of dedicated service with Anika,&#8221; Sherwood said.
      &#8220;We look forward to Kevin&#8217;s continued contributions during the
      transition process in the weeks ahead, and wish him success in his
      future endeavors.&#8221;
    </p>
    <p>
      <b>Preliminary Financial Results</b>
    </p>
    <p>
      Based on preliminary unaudited information and subject to the year-end
      accounting close and audit, Anika expects total revenue for the fourth
      quarter ended December 31, 2012 in the range of $22.0 million to $23.0
      million, compared with $18.4 million in the fourth quarter of 2011. For
      full-year 2012, total revenue is expected to be between $70.0 million
      and $71.6 million, compared with $64.8 million a year earlier.
    </p>
    <p>
      Anika expects to equal or exceed its previously announced guidance of
      $0.74 net income per diluted share for full-year 2012. This includes, as
      announced on December 28, 2012, a pre-tax charge of approximately $2.5
      million related to the closure of the company&#8217;s tissue engineering
      facility in Abano Terme, Italy.
    </p>
    <p>
      &#8220;Anika delivered solid revenue growth in the fourth quarter of 2012,
      concluding an excellent year from both operational and financial
      perspectives,&#8221; said Sherwood. &#8220;Our top-line performance continues to be
      driven by strong worldwide demand for our flagship orthobiologics
      product Orthovisc<sup>&#174;</sup>. On the bottom line, improvements in
      our operating efficiency, coupled with growing revenue, have enabled us
      to drive continued growth in income from operations and strong cash
      flow.&#8221;
    </p>
    <div style="margin-right: 0pt; text-indent: 0pt; margin-left: 0pt; width: 100%; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      <b>Fourth Quarter 2012 Conference Call</b>
    </p>
    <p>
      Anika expects to release its final financial results for the quarter and
      year ended December 31, 2012 on Wednesday, February 27, 2013. The
      company plans to hold a conference call the next day, Thursday, February
      28, 2013, at 9:00 a.m. ET, to discuss its financial results, business
      highlights and outlook. In addition, management will answer questions
      concerning business and financial developments and trends, and other
      business and financial matters affecting the company, some of the
      responses to which may contain information that has not been previously
      disclosed.
    </p>
    <p>
      To listen to the conference call, dial 800-291-5365 (international
      callers dial 617-614-3922) and use the passcode 89264114. In addition,
      the call will be available through a live audio webcast in the &quot;Investor
      Relations&quot; section of Anika&#8217;s website, <u>www.anikatherapeutics.com</u>.
      An accompanying slide presentation also can be accessed via the Anika
      Therapeutics website. The call will be archived and accessible on the
      same website shortly after its conclusion.
    </p>
    <p>
      <b>About Anika Therapeutics, Inc.</b>
    </p>
    <p>
      Headquartered in Bedford, Mass., Anika Therapeutics, Inc. develops,
      manufactures and commercializes therapeutic products for tissue
      protection, healing, and repair. These products are based on hyaluronic
      acid (HA), a naturally occurring, biocompatible polymer found throughout
      the body. Anika&#8217;s products range from orthopedic/joint health solutions
      led by Orthovisc<sup>&#174;</sup>, a treatment for osteoarthritis of the
      knee; to surgical aids in the ophthalmic and anti-adhesion fields. The
      company also offers aesthetic dermal fillers for the correction of
      facial wrinkles. Anika&#8217;s Italian subsidiary, Anika Therapeutics, S.r.l,
      provides complementary HA products in orthopedic/joint health and
      anti-adhesion, as well as therapeutics in new areas such as advanced
      wound treatment and ear, nose and throat care. Its regenerative
      technology advances Anika&#8217;s vision to offer therapeutic products that go
      beyond pain relief to protect and restore damaged tissue.
    </p>
    <p>
      <i>The statements made in this press release which are not statements of
      historical fact are forward-looking statements within the meaning of
      Section 27A of the Securities Act of 1933, as amended, and Section 21E
      of the Securities Exchange Act of 1934, as amended. These statements
      include, but are not limited to, those relating to the appointment of
      Sylvia Cheung as Anika&#8217;s Chief Financial Officer, effective April 1,
      2013; the departure of Kevin Quinlan as the company&#8217;s Chief Financial
      Officer effective March 31, 2013; Mr. Quinlan&#8217;s continued service as
      Chief Financial Officer and assistance with the CFO transition process
      through March 31, 2013; and Anika&#8217;s expectations regarding its financial
      results for the fourth quarter and year ended December 31, 2012. These
      statements are based upon the current beliefs and expectations of the
      company's management and are subject to significant risks, uncertainties
      and other factors. The company's actual results could differ materially
      from any anticipated future results, performance or achievements
      described in the forward-looking statements as a result of a number of
      factors including (i) the company's ability to successfully commence
      and/or complete clinical trials of its products on a timely basis or at
      all, obtain clinical data to support a pre-market approval application
      or timely file and receive FDA or other regulatory approvals or
      clearances of its products, or that such approvals will not be obtained
      in a timely manner or without the need for additional clinical trials,
      other testing or regulatory submissions, as applicable; (ii) the
      company's research and product development efforts and their relative
      success, including whether the company has any meaningful sales of any
      new products resulting from such efforts; (iii) the cost effectiveness
      and efficiency of our clinical studies, manufacturing operations and
      production planning; (iv) the strength of the economies in which the
      company operates or will be operating, as well as the political
      stability of any of those geographic areas; (v) future determinations by
      the company to allocate resources to products and in directions not
      presently contemplated, (vi) the company&#8217;s ability to launch Monovisc in
      the U.S., if at all; (vii) the company&#8217;s ability to successfully resolve
      its appeal hearing regarding the FDA&#8217;s non-approvable letter for
      Monovisc, and the timing and results of such review; (viii) the
      company&#8217;s ability to provide an adequate and timely supply of its
      ophthalmic, Orthovisc and other products to its customers, (ix) our
      ability to successfully manage and turnaround Anika S.r.l.&#8217;s business;
      (x) the company&#8217;s ability to achieve its stated growth targets; (xi) the
      risk that the company does not achieve the operational or financial
      results that it expects and (xii) the risk that changes to the company&#8217;s
      preliminary results will be required as a result of completing the
      financial reporting closing process and financial audit.</i> <i>Certain
      other factors that might cause the company's actual results to differ
      materially from those in the forward-looking statements include those
      set forth under the headings &quot;Business,&quot; &quot;Risk Factors&quot; and
      &quot;Management's Discussion and Analysis of Financial Condition and Results
      of Operations&quot; in the company's Annual Report on Form 10-K for the year
      ended December 31, 2011, as well as those described in the company's
      other press releases and SEC filings.</i>
    </p>
    <p style="text-align: center">

    </p>
    <p>
      CONTACT:<br>Anika Therapeutics, Inc.<br>Charles H. Sherwood, Ph.D., CEO<br>781-457-9000
    </p>
    <p style="white-space: nowrap">

    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
